Tp 1287 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA has granted an orphan drug designation to TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma.

Sumitomo dainippon pharmaJatinj shahPatricias andrewsSumitomo pharma oncology incSumitomo pharma oncologySumitomo pharmaPharma oncologyDainippon pharma oncologyDainippon pharmaTp 1287Ewing sarcomaCdk9 inhibitor